Avidia Acquired by Amgen
Thousand Oaks-based Amgen acquired Mountain View-based Avidia, a biopharmaceutical company that develops human therapeutics for the treatment of inflammation and autoimmune diseases. The deal, which was announced Friday, is worth $290M in cash, and up to $90M in earnout. Avidia's lead product candidate, inhibitor of interleukin 6 (IL-6) for the treatment of inflammation and autoimmune diseases, is in Phase 1 clinical trials.
posted on Monday, October 2, 2006
Related stories:
> Avidia Acquisition Completes
> Onyx Pharmaceuticals Acquired By Amgen For $10.4 Billion
> KAI Pharmaceuticals Acquired By Amgen For $315M
> Relypsa Gets $33M, Spins Out of Amgen-Ilypsa
> Flexus Biosciences Acquired For $1.25 Billion
silicontap.com Home